DR. KIRSTEN GRÜNEBERG
Partner
Dr. Kirsten A. Grüneberg co-founded Grüneberg and Myers PLLC in 2017. Less than 3 years later, the firm was listed in IAM Patent 1000 by Intellectual Asset Management as one of the world's leading IP firms. Dr. Grüneberg has the rare honor of being listed repeatedly in IAM Patent 1000 as well as IAM Strategy 300 naming the world's top IP professionals and IP strategists. In addition, Dr. Grüneberg was honored as an IP Star by Managing Intellectual Property (MIP) and a Life Science Star by LMG Life Sciences. IAM notes: “A model of flexibility, speed, cost effectiveness and quality, forward-looking Tysons, Virginia patent boutique Grüneberg and Myers has recorded striking growth of late. With prosecution the bedrock of its practice, the ensemble has been structuring robust protection for a host of global companies across multiple industries. It is not just a filing shop, though; strategic value is packed into every direction it provides on matters such as product clearance. Taking charge is Kirsten A Grüneberg, a chemical, biotech and pharmaceutical expert who provides ‘quick, straightforward but thorough advice’ and ‘achieves the maximum scope of protection in the most efficient way’. …Grüneberg has hired astutely, too, selecting individuals with in-house experience, international expertise and technical fluency.”
Dr. Grüneberg represents many of the world’s largest chemical, biotech, and pharmaceutical companies, including US Fortune 50 and Global Fortune 200 companies, several DAX 30 companies in Germany as well as Nikkei 225 companies in Japan.
In 2021, Dr. Grüneberg was a finalist for the "Patent Strategy Attorney of the Year" LMG Life Sciences Awards in the DC Area. She has successfully defended high value pharma patents in post-grant proceedings, helping to secure business deals worth several hundreds of millions of dollars. Dr. Grüneberg also has significant experience in Hatch-Waxman related matters (including patent term extension, Orange Book listings, and IP-related aspects of FDA submissions) as well as IP issues in connection with mergers and acquisitions in the U.S., Germany, Switzerland, Japan, and China.
Areas of technical expertise further include polymers, automotive additives, coatings, toners, 3D-printing technology, Industry 4.0, adhesives, building materials, pharmaceuticals including small molecules and biologics, medical devices, diagnostics, drug delivery systems, specialty chemicals including pigments, catalysts, lubricants, liquid crystals, surfactants, surface modified materials, nanotechnology, semiconductors, and battery materials.
Dr. Grüneberg is active in the areas of opinions and counseling, post-grant proceedings including inter partes review and reexaminations, intellectual property portfolio management and development, chemical as well as pharmaceutical/medical devices patent prosecution. She is a native German speaker and regularly visits clients in Europe and Asia to update them about the latest developments in U.S. patent law and to work closely with them on selected high-profile projects.
Dr. Grüneberg is a contributor to the treatise entitled Post-Grant Proceedings Before the Patent Trial and Appeal Board, published by Practicing Law Institute. The treatise guides readers through the process of initiating a post-grant proceeding, taking discovery, seeking sanctions, proposing and opposing claim amendments, effectively advocating at the oral hearing, appealing to the Federal Circuit, and handling a wide array of issues involving co-pending district court litigation.
After receiving her Ph.D. in organic chemistry, magna cum laude, from the Technische Universität Berlin in Germany, Dr. Grüneberg was awarded a Lynen-Fellowship from the Alexander von Humboldt Foundation in Germany. This fellowship was to perform research during a three-year period at the Center for Bio/Molecular Science and Engineering of the U.S. Naval Research Laboratory. She was a visiting professor at the Georgetown University Medical Center and also worked as a senior scientist at Geo-Centers, Inc./U.S. Naval Research Laboratory and as a research scientist at the Max-Planck-Institute of Colloids and Interfaces in Berlin. Dr. Grüneberg received her Masters of Science in organic chemistry, summa cum laude, and her Bachelors of Science in chemistry/chemical engineering, magna cum laude, from the E.-M.-Arndt-University in Germany.
Dr. Grüneberg has published more than 50 scientific papers and conference presentations in the areas of liquid crystals, display technology, organic thin films, polymers, surfactants, and antimicrobial materials. She has been an invited speaker regarding her research at international conferences in the U.S., Japan, Germany, Italy, Switzerland, and South Korea, and is an inventor on several U.S. and foreign patents.